Related references
Note: Only part of the references are listed.A critical role for Lyn in acute myeloid leukemia
Ceric Dos Santos et al.
BLOOD (2008)
Molecular characterization of acute myeloid leukemia and its impact on treatment
Olga Frankfurt et al.
CURRENT OPINION IN ONCOLOGY (2007)
AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo
Jing Yang et al.
BLOOD (2007)
A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia
Takayuki Ikezoe et al.
MOLECULAR CANCER THERAPEUTICS (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
Polo-like kinase 3 is required for entry into S phase
Wendy C. Zimmerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Expression of PLK1 and survivin in diffuse large B- cell lymphoma
Lin Liu et al.
LEUKEMIA & LYMPHOMA (2007)
Polo-like kinase 1 - Target and regulator of transcriptional control
Bernd T. Martin et al.
CELL CYCLE (2006)
Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia
Anne Fernandez-Vidal et al.
CANCER RESEARCH (2006)
Polo-like kinases - A team in control of the division
Barbara C. M. van de Weerdt et al.
CELL CYCLE (2006)
Opinion - Targeting polo-like kinase 1 for cancer therapy
K Strebhardt et al.
NATURE REVIEWS CANCER (2006)
Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies
N Syed et al.
BLOOD (2006)
p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2
MW Jackson et al.
JOURNAL OF CELL SCIENCE (2005)
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
K Gumireddy et al.
CANCER CELL (2005)
Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas
K Mito et al.
LEUKEMIA & LYMPHOMA (2005)
FoxM1 is required for execution of the mitotic programme and chromosome stability
J Laoukili et al.
NATURE CELL BIOLOGY (2005)
Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues
JA Winkles et al.
ONCOGENE (2005)
Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner
G de Cárcer
CANCER RESEARCH (2004)
Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells
J Ekberg et al.
ONCOGENE (2004)
β-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1)
Y Masuda et al.
ONCOGENE (2003)
The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition
DM Kang et al.
JOURNAL OF CELL BIOLOGY (2002)
Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1
C Liao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
